Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.

Shaikh MH, Idris A, Johnson NW, Fallaha S, Clarke DTW, Martin D, Morgan IM, Gabrielli B, McMillan NAJ.

Oral Oncol. 2018 Nov;86:105-112. doi: 10.1016/j.oraloncology.2018.09.006. Epub 2018 Sep 19.

PMID:
30409290
2.

Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.

Tayyar Y, Jubair L, Fallaha S, McMillan NAJ.

Crit Rev Oncol Hematol. 2017 Nov;119:59-65. doi: 10.1016/j.critrevonc.2017.09.006. Epub 2017 Sep 18. Review.

PMID:
29065986
3.

Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.

Martin D, Fallaha S, Proctor M, Stevenson A, Perrin L, McMillan N, Gabrielli B.

Mol Cancer Ther. 2017 Sep;16(9):1934-1941. doi: 10.1158/1535-7163.MCT-17-0159. Epub 2017 May 18.

4.

Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.

Gabrielli B, Bokhari F, Ranall MV, Oo ZY, Stevenson AJ, Wang W, Murrell M, Shaikh M, Fallaha S, Clarke D, Kelly M, Sedelies K, Christensen M, McKee S, Leggatt G, Leo P, Skalamera D, Soyer HP, Gonda TJ, McMillan NA.

Mol Cancer Ther. 2015 Dec;14(12):2753-61. doi: 10.1158/1535-7163.MCT-15-0506. Epub 2015 Oct 29.

5.

Broadening GHG accounting with LCA: application to a waste management business unit.

Fallaha S, Martineau G, BĂ©caert V, Margni M, DeschĂȘnes L, Samson R, Aoustin E.

Waste Manag Res. 2009 Nov;27(9):885-93. doi: 10.1177/0734242X09352505. Epub 2009 Oct 23.

PMID:
19854813

Supplemental Content

Loading ...
Support Center